This work sets the stage for future studies where we will refine the NF1 morphology signature using a broader panel of Schwann cell lines (including primary Schwann cells), and apply high-throughput phenotypic drug discovery to identify therapeutic agents that elevate wildtype neurofibromin levels, potentially slowing or reversing tumor development in NF1 patients. Here, NF1 is linked to neoplasm.